UK Markets closed

H. Lundbeck A/S (0ND5.IL)

IOB - IOB Delayed price. Currency in DKK
Add to watchlist
25.70+0.04 (+0.14%)
At close: 06:12PM GMT

H. Lundbeck A/S

Ottiliavej 9
Valby 2500
Denmark
45 36 30 13 11
https://www.lundbeck.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full-time employees5,437

Key executives

NameTitlePayExercisedYear born
Dr. Deborah Dunsire M.D.Pres & CEO52.4MN/A1962
Mr. Jacob TolstrupExec. VP of Commercial Operations & Chief Commercial Officer6.5MN/A1972
Mr. Lars BangExec. VP of Product Devel. & Supply6.7MN/A1962
Dr. Per Johan LuthmanExec. VP of R&D6.6MN/A1959
Mr. Joerg HornsteinCFO & Exec. VP of Corp. FunctionsN/AN/A1977
Dr. Tarek Samad Ph.D.Sr. VP & Head of ResearchN/AN/AN/A
Mr. Palle Holm OlesenChief Specialist & VP of Investor RelationsN/AN/AN/A
Ms. Elise HaugeExec. VP of People & CommunicationN/AN/A1967
Mr. Ole ChrintzSr. VP of International MarketsN/AN/A1958
Mr. Keld Flintholm JorgensenExec. VP of Corp. Strategy & Bus. Devel.N/AN/A1971
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in DKK.

Description

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

Corporate governance

H. Lundbeck A/S’s ISS governance QualityScore as of 1 October 2022 is 3. The pillar scores are Audit: 3; Board: 4; Shareholder rights: 1; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.